Cancer biomarkers : section A of Disease markers最新文献

{"title":"Prognostic significance of LAPTM4B and p27kip1 expression in triple-negative breast cancer.","authors":"Xuelu Li,&nbsp;Chen Song,&nbsp;Kainan Wang,&nbsp;Ning Li,&nbsp;Siwen Sun,&nbsp;Na Li,&nbsp;Zuowei Zhao,&nbsp;Man Li","doi":"10.3233/CBM-182094","DOIUrl":"https://doi.org/10.3233/CBM-182094","url":null,"abstract":"<p><strong>Backgroud: </strong>Triple-negative breast cancer (TNBC) is associated with an aggressive phenotype and poor prognosis, and the lack of druggable markers leads to the unavailability of targeted therapies. Thus, there is an urgent need to identify potential targets for triple-negative breast cancer.</p><p><strong>Objective: </strong>In this study, we aimed to explore the expression of LAPTM4B and p27kip1 in triple-negative breast cancer, and its clinical significance.</p><p><strong>Methods: </strong>We analyzed the expression and association of LAPTM4B and p27kip1 in human breast cancer databases. To analyze the role of LAPTM4B in the aggressiveness of the human triple-negative breast cancer, the expressions of LAPTM4B were knocked down in MDA-MB-231 and HCC1187 cell lines. Then, cell proliferation, migration and apoptosis were assessed in vitro. Furthermore, the immunohistochemistry examinations of LAPTM4B and p27kip1 expression were performed using surgical specimens from 188 primary triple-negative breast cancer patients.</p><p><strong>Results: </strong>Through analyses of several independent breast cancer cohorts, we found the correlation of the LAPTM4B and p27kip1 expression. Remarkably, the knockdown of LAPTM4B restored p27kip1 expression and inhibited the aggressiveness of breast cancer cells. Meanwhile, the knockdown of p27kip1 relieved the suppression of cell migration. Consistent with the analyses of human breast cancer cohorts, the immunohistochemistry results showed that the expression levels of LAPTM4B and p27kip1 were correlated in 188 triple-negative breast cancer samples (p= 0.019). We also validated that the higher LAPTM4B expression, the lower p27kip1 expression (p= 0.0001), and the LAPTM4B+/p27kip1- subgroup (p< 0.0001) were poor prognostic indicators, as well as the higher histologic grade (p= 0.0001). In the multivariate Cox regression, p27kip1 expression was considered as an independent predictor of survival (p< 0.001).</p><p><strong>Conclusions: </strong>The overexpression of LAPTM4B and the loss of p27kip1 expression are correlated. Meanwhile, the up-regulated expression of LAPTM4B together with the down-regulated expression of p27kip1 could classified a group of breast cancer patients with poor prognosis, consequently considered as a potentially prognostic marker and candidate target for therapeutic intervention of triple-negative breast cancer.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":" ","pages":"19-27"},"PeriodicalIF":3.1,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/CBM-182094","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37195369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MicroRNA-98 targets HMGA2 to inhibit the development of retinoblastoma through mediating Wnt/β-catenin pathway.","authors":"Wei Li,&nbsp;Junmei Wang,&nbsp;Dongqing Zhang,&nbsp;Xiting Zhang,&nbsp;Jumei Xu,&nbsp;Li Zhao","doi":"10.3233/CBM-182315","DOIUrl":"https://doi.org/10.3233/CBM-182315","url":null,"abstract":"<p><strong>Background: </strong>Recently, the incidence and mortality of retinoblastoma (RB) have gradually increased. Many studies support the pivotal role of microRNAs (miRNAs) in the pathogenesis of RB. Alternation of microRNA-98 (miR-98) expression has been detected in several cancers, excluding RB. This study was designed to assess the regulatory mechanisms of miR-98 in human RB.</p><p><strong>Methods: </strong>RT-qPCR and Western blot analysis were used to detect miR-98 and HMGA2 expression. The effects of miR-98 were explored using the CCK-8 and Transwell assays. Dual-luciferase reporter assay was performed to confirm the relationship between miR-98 and HMGA2.</p><p><strong>Results: </strong>In RB, downregulation of miR-98 was identified. Upregulation of miR-98 inhibited proliferation, invasion and migration of RB cells. Further, HMGA2 was confirmed as a direct target gene of miR-98. And knockdown of HMGA2 suppressed the progression of RB. Moreover, upregulation of HMGA2 reversed the suppressive effects in the development of RB. In addition, miR-98 also showed suppressive effect on EMT and Wnt/β-catenin pathway.</p><p><strong>Conclusion: </strong>MiR-98 targets HMGA2 to act as a tumor suppressor in RB by mediating Wnt/β-catenin pathway.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":" ","pages":"79-88"},"PeriodicalIF":3.1,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/CBM-182315","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37356522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Downregulation of long noncoding RNA LINC00460 expression suppresses tumor growth in vitro and in vivo in gastric cancer.","authors":"Shuhua Zhang,&nbsp;Jianqun Xu,&nbsp;Hongjuan Wang,&nbsp;Hongrong Guo","doi":"10.3233/CBM-182177","DOIUrl":"https://doi.org/10.3233/CBM-182177","url":null,"abstract":"<p><strong>Background: </strong>Long noncoding RNA have been indicated to be involved in tumor development. However, the role of LINC00460 in gastric cancer (GC) still remains large unknown. The current study is designed aiming at determining the effects of LINC00460 on GC progression.</p><p><strong>Patients and methods: </strong>The expression of LINC00460 in GC tissues and cells were detected by quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). The cell proliferation, cell cycle distribution and cell invasion were evaluated by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide), flow cytometry analysis and transwell cell invasion assays. Western blot analysis was used to detect the WNT signaling related protein expression. Tumor xenograft assay was used to detect the effects of LINC00460 in vivo.</p><p><strong>Results: </strong>In the study, we demonstrated that LINC00460 expression was higher in gastric cancer tissues compared to adjacent normal tissues. Higher LINC00460 expression associated with lymph node metastasis and advanced TNM stage. Furthermore, we showed that higher LINC00460 expression predicted a poor disease-free survival (DFS) and overall survival (OS) time of gastric cancer. Multivariate analysis showed that LINC00460 expression was an independent risk factor of GC prognosis. Furthermore, in vitro, we demonstrated that inhibition of LINC00460 expression suppressed cell proliferation, S phase cell number and cell invasion of gastric cancer cells compared to the control groups. In addition, we showed that downregulation of LINC00460 inhibited the Wnt/β-catenin signaling by downregulating c-Myc and β-catenin expression, which indicated LINC00460 could promote cell proliferation and invasion by activating Wnt/β-catenin signaling. In vivo, we also demonstrated that LINC00460 knockdown significantly suppressed cell proliferation.</p><p><strong>Conclusions: </strong>LINC00460 is a new type of molecule involved in the development of GC, which may become a potential target for the treatment of GC.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":" ","pages":"429-437"},"PeriodicalIF":3.1,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/CBM-182177","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37088544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical response and prognostic significance of serum miR-497 expression in colorectal cancer.","authors":"Guicheng Zou,&nbsp;Rui Wang,&nbsp;Minghui Wang","doi":"10.3233/CBM-181902","DOIUrl":"https://doi.org/10.3233/CBM-181902","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is a common type of cancer around the world. Detection of microRNA (miRNA) aberration in blood samples is a novel approach for CRC screening.</p><p><strong>Objective: </strong>The purpose of this study was to explore the serum miR-497 expression pattern in CRC and examine its potential usefulness as a biomarker for CRC diagnosis and prognosis.</p><p><strong>Methods: </strong>Serum miR-497 expression was evaluated by quantitative reverse transcription polymerase chain reaction (qRT-PCR) in 110 patients with CRC, 35 cases with colorectal adenoma, 54 cases with colorectal polyps, and 70 healthy individuals.</p><p><strong>Results: </strong>The expression level of miR-497 was significantly downregulated in CRC tissues compared to the normal tissues based on the data from three independent studies GSE68204, GSE41655 and GSE35834. Compared to healthy controls, the serum miR-497 level was significantly decreased in patient with CRC or benign lesion (colorectal adenoma and polyps). Serum miR-497 level was dramatically increased in the post-operative blood samples from early stage CRC patients. Receiver-operating characteristic (ROC) analysis showed that serum miR-497 had a high sensitivity and specificity for discriminating CRC or precancerous colorectal lesion from normal controls. Moreover, low serum miR-497 expression was closely correlated with aggressive clinical features and shorter overall survival (OS). Kaplan-Meier analyses also revealed that OS was strongly associated with lymph node invasion, TNM stage and histological grade. Furthermore, univariate and multivariate analysis showed serum miR-497 was an independent prognostic factor for CRC.</p><p><strong>Conclusions: </strong>Collectively, serum miR-497 may serve as a promising biomarker for diagnosis and prognosis of CRC.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":" ","pages":"11-18"},"PeriodicalIF":3.1,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/CBM-181902","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37172679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methylation of tumour suppressor genes associated with thyroid cancer.","authors":"Anca Botezatu,&nbsp;Iulia V Iancu,&nbsp;Adriana Plesa,&nbsp;Dana Manda,&nbsp;Oana Popa,&nbsp;Marinela Bostan,&nbsp;Mirela Mihaila,&nbsp;Adrian Albulescu,&nbsp;Alina Fudulu,&nbsp;Susana V Vladoiu,&nbsp;Irina Huica,&nbsp;Ruxandra Dobrescu,&nbsp;Gabriela Anton,&nbsp;Corin Badiu","doi":"10.3233/CBM-182265","DOIUrl":"https://doi.org/10.3233/CBM-182265","url":null,"abstract":"<p><strong>Background: </strong>Thyroid carcinoma is the most common endocrine malignancy worldwide. Changes in DNA methylation can cause silencing of normally active genes, especially tumour suppressor genes (TSG) or activation of normally silent genes.</p><p><strong>Objective: </strong>The aim of this study is to evaluate the degree of promoter methylation for a panel of markers for thyroid neoplasms and to establish their relationship with thyroid oncogenesis.</p><p><strong>Methods: </strong>To generate a comprehensive DNA methylation signature of TSGs involved in thyroid neoplasia, we use Human TSG EpiTect Methyl II Signature PCR Array-Qiagen for 24 samples (follicular adenomas and papillary thyroid carcinomas) compared with normal thyroid tissue. We extended the evaluation for three TSGs (TP73, WIF1, PDLIM4) using qMS-PCR. Statistical analysis was performed with GraphPad Prism.</p><p><strong>Results: </strong>We noted four important genes NEUROG1, ESR1, RUNX3, MLH1, which presented methylated promoter in tumour samples compared to normal. We found new characteristic of thyroid tumours: methylation of TP73, WIF1 and PDLIM4 TSGs, which can contribute to thyroid neoplasia. A significant correlation between BRAF V600E mutation and RET/PTC rearrangements with TIMP3 and CDH13, RARB methylation, respectively was observed.</p><p><strong>Conclusions: </strong>TSGs promoter hypermethylation is a hallmark of cancer and a test that uses methylation quantification method is suitable for diagnosis and prognosis of thyroid cancer.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":" ","pages":"53-65"},"PeriodicalIF":3.1,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/CBM-182265","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37172680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MiR-342 regulates cell proliferation and apoptosis in hepatocellular carcinoma through Wnt/β-catenin signaling pathway.","authors":"Chang Lu,&nbsp;Shengnan Jia,&nbsp;Shutao Zhao,&nbsp;Xue Shao","doi":"10.3233/CBM-192399","DOIUrl":"https://doi.org/10.3233/CBM-192399","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is one of the most common malignancies, and its global morbidity and mortality are increasing. Previous studies confirmed that miR-342 was involved in the development and progression of malignant tumors. However, the relationship between miR-342 and Wnt/β-catenin signaling pathway in HCC remains unknown.</p><p><strong>Materials and methods: </strong>Cell viability was detected by MTT assay. Immunofluorescence staining was used to detect Brdu-positive cells and Western blot was used to detect the apoptotic proteins. Furthermore, linear correlation analysis was used to investigate the possible relationship between miR-342 and the downstream genes of Wnt/β-catenin signaling pathway in the progression of HCC.</p><p><strong>Results: </strong>Over-expression of miR-342 significantly reduced cell proliferation and obviously increased apoptosis in HCC, while silencing of miR-342 showed an opposite effect on HCC cell proliferation and apoptosis. In addition, we found that the CXCL12 was the target gene of miR-342. This study also demonstrated that miR-342 up-regulation suppressed Wnt/β-catenin signaling pathway by inhibiting CXCL12 expression.</p><p><strong>Conclusion: </strong>Up-regulation of miR-342 inhibited cell proliferation and induced cell apoptosis in HCC by inhibiting Wnt/β-catenin signaling pathway, suggesting that miR-342 might act as a promising tumor gene therapeutic target for HCC patients.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":" ","pages":"115-126"},"PeriodicalIF":3.1,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/CBM-192399","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37334219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Positive BCL2L12 expression predicts favorable prognosis in patients with laryngeal squamous cell carcinoma.","authors":"Aris I Giotakis,&nbsp;Andreas C Lazaris,&nbsp;Agapi Kataki,&nbsp;Christos K Kontos,&nbsp;Evangelos I Giotakis","doi":"10.3233/CBM-181772","DOIUrl":"https://doi.org/10.3233/CBM-181772","url":null,"abstract":"<p><strong>Background: </strong>Laryngeal squamous cell carcinoma (LSCC) constitutes the third most frequent head and neck cancer. Several tissue biomarkers have been studied for their prognostic significance in LSCC.</p><p><strong>Objective: </strong>To investigate the prognostic significance of BCL2L12, a new member of the BCL2 family, in primary LSCC along with well-examined biomarkers such as BCL2 and BAX.</p><p><strong>Methods: </strong>Cancerous tissue specimens of patients with primary LSCC were collected during 2005 and 2012 as pretreatment tissue biopsy. The specimens were immunohistochemically evaluated for the protein expression of BCL2L12, BCL2 and BAX. Kaplan-Meier survival curves and Cox proportional hazard regression models were performed to evaluate prognosis.</p><p><strong>Results: </strong>In the study cohort of 78 patients with primary LSCC, Kaplan-Meier survival curves demonstrated that advanced-stage LSCC patients with BCL2L12-positive tumors had significantly higher OS time in comparison with advanced-stage LSCC patients with BCL2L12-negative tumors (p= 0.014). Also, advanced-stage LSCC patients with BCL2L12-positive tumors had significantly lower risk of death from LSCC compared to advanced-stage LSCC patients with BCL2L12-negative tumors (HR = 0.228, 95%CI = 0.063-0.833, p= 0.025).</p><p><strong>Conclusions: </strong>BCL2L12 protein expression could be used as a favorable prognostic tissue biomarker in patients with primary advanced-stage LSCC. On the contrary, BCL2 and BAX did not correlate with prognosis in patients with primary LSCC.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":" ","pages":"141-149"},"PeriodicalIF":3.1,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/CBM-181772","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37255732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.3233/CBM-189863","DOIUrl":"https://doi.org/10.3233/CBM-189863","url":null,"abstract":"","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":" ","pages":"523"},"PeriodicalIF":3.1,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/CBM-189863","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37087521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical significance of serum miR-25 as a diagnostic and prognostic biomarker in human gastric cancer.","authors":"Ying Kong,&nbsp;Liang Ning,&nbsp;Fei Qiu,&nbsp;Qian Yu,&nbsp;Bin Cao","doi":"10.3233/CBM-182213","DOIUrl":"https://doi.org/10.3233/CBM-182213","url":null,"abstract":"<p><strong>Background and objective: </strong>MicroRNAs (miRNAs) are under investigation as novel diagnostic and prognostic biomarkers in several malignancies, including gastric cancer (GC). miR-25 was overexpressed in GC tissues, and higher miR-25 expression was statistically correlated with aggressive clinicopathological characteristics. In our study, we investigate the associations of serum miR-25 level with the clinicopathological characteristics, diagnosis and prognosis of GC patients.</p><p><strong>Methods: </strong>Serum samples from 184 GC patients, 56 gastritis patients and 78 healthy controls were subjected to real-time quantitative polymerase chain reaction (RT-qPCR), and the relationship between micR-25 level and cliniopathological characteristics including diagnosis and prognosis was explored.</p><p><strong>Results: </strong>Compared with the gastritis and healthy patients, serum miR-25 level was significantly up-regulated in patients with GC. Using a cut-off of 0.042, the level of miR-25 was significantly increased in serum samples from cancer patients; Using this test cancer patients were identified with 67.3-69.4% sensitivity and 80.4%-81.0% specificity. High serum miR-25 level was significantly associated with depth of invasion, lymph node metastasis and stage of disease. In univariate and multivariate analyses, miR-25 was an independent prognostic factor for overall survival (OS). Moreover, high serum miR-25 level was correlated with poor prognosis in patients subgroups stratified by tumor size, depth of invasion and lymph node metastasis. Serum miR-25 level was increased in both prominent serosal invasion group and lymph node metastasis group. Furthermore, stratified analysis showed that the TNM stage I-VI patients with high serum miR-25 level had poor prognosis than those with low serum miR-25 level.</p><p><strong>Conclusions: </strong>Serum levels of miR-25 could improve gastric cancer screening, and as the better diagnostic and prognostic marker of gastric cancer.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":" ","pages":"477-483"},"PeriodicalIF":3.1,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/CBM-182213","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37088546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of AIB1 expression on the prognosis of upper tract urothelial carcinoma after radical nephroureterectomy.","authors":"Yong Huang,&nbsp;Junjie Cen,&nbsp;Jinhuan Wei,&nbsp;Zhenhua Chen,&nbsp;Yong Fang,&nbsp;Zihao Feng,&nbsp;Jun Lu,&nbsp;Yanping Liang,&nbsp;Junhang Luo,&nbsp;Chengqiang Mo,&nbsp;Wei Chen","doi":"10.3233/CBM-182020","DOIUrl":"https://doi.org/10.3233/CBM-182020","url":null,"abstract":"<p><strong>Background: </strong>Amplified in breast cancer 1 (AIB1) is a candidate oncogene in human breast cancer, which has been identified to be amplified and overexpressed in several types of other human cancers. Abnormalities of AIB1 and its clinical/prognostic significance, however, in upper tract urothelial carcinoma (UTUC) remain unclear.</p><p><strong>Objective: </strong>To explore what role AIB1 plays in upper tract urothelial carcinoma.</p><p><strong>Methods: </strong>The expression of AIB1 was analyzed using immunohistochemical staining in 133 UTUC patients. Overall, cancer specific and recurrence-free survival rates (OS, CSS, and RFS) were estimated using the Kaplan-Meier method. Multivariable COX regression models containing relevant clinicopathological variables addressed the prediction of postoperative outcome.</p><p><strong>Results: </strong>High AIB1 expression was observed to be associated with increased hazard ratios for 5-year CSS (80.6% vs. 55.8%, p= 0.008) and OS (78.1% vs. 54.8%, p= 0.006). Multivariable analysis revealed that elevated AIB1 expression was an independent prognostic predictor of OS, CSS and RFS. Additionally, pT, pN and hydronephrosis were independently associated with oncologic outcome of UTUC. Three proposed nomograms were proposed to provide an individualized risk estimate of postoperative outcome in patients with UTUC.</p><p><strong>Conclusions: </strong>AIB1 can be used as an independent molecular marker for the prognosis of clinical outcomes of UTUC.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":" ","pages":"151-160"},"PeriodicalIF":3.1,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/CBM-182020","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37366761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}